Drug Safety 2018

SMi Group11 - 12 June 2018, London, UK.
SMi Group are delighted to announce their 5th Drug Safety conference. For drugs anywhere, it's the safety in patients which is a huge issue, constantly under surveillance, irrespective of where the drug is in its pipeline.

The Global Pharmaceutical Market currently has a market value of $1057 billion. If a drug is found to be unsafe, causing serious side effects, it can have a huge knock on effect on revenue, causing huge losses to pharmaceutical companies manufacturing the drug.

Drug Safety 2018 aims to discuss the latest findings and current thinking on pharmacovigilance. Importantly, it will address the newest regulatory updates and interpretations of them, including the impact of the vital and much awaited Clinical Trial Regulations.

Network and learn from leading professionals such as:

Keynote Speakers

  • David Lewis, Senior Adviser Pharmacovigilance, CMO Patient Safety, Novartis
  • Peter De Veene, Senior Vice President and Head Global Drug Safety and QPPV, Grünenthal
  • Simon Ashworth, VP EU QPPV, EU Head Compliance and Marketed Products and Head PV Affiliate Relations, Takeda

Regulatory Speaker

  • Kirsty Wydenbach, Deputy Unit Manager, Clinical Trials Unit, MHRA

Pharmaceutical Speakers:

  • John Solomon, Head of Pharmacovigilance-UK & Ireland, Sanofi
  • Bjarke Naver, Head of Pharmacovigilance Science, LEO Pharma
  • Sue Rees, EU QPPV, Executive Director, Global Safety, Amgen
  • Jackie Roberts, Executive Director Regulatory, Pharmacovigilance and Medical UK/IE/Malta and MENA, Accord Healthcare
  • Philip Eichorn, Senior Director, Worldwide Safety and Regulatory, Pfizer
  • Rawya Al Kredly, Director of Medical Affairs Department, Gulf Pharmaceutical Industries (Julphar)
  • Bert van Leeuwen, Deputy QPPV, Astellas
  • Kashif Sheikh, Safety Surveillance Specialist, Novo Nordisk

Featured Highlights:

  • MHRA spotlight presentation on the future of Clinical Trial Regulations
  • Hear first experiences with the new Eudravigilence system
  • Gain insight into how competitors are reporting adverse effects under the new legislation and system
  • Discuss risk-minimisation and signal detection strategies with industry-thought leaders
  • Evaluate the benefits and pitfalls of patient involvement and patient support programs

For further information and to register, please visit:
http://www.drugsafetyconference.co.uk/wpn

Early-Bird Rates

  • Book by 28th February and save £400
  • Book by 29th March and save £200
  • Book by 30th April and save £100

About SMi Group

The SMi Group is a highly Professional, Independent and Global company that specialises in the production of Business-to-Business Conferences, Workshops and Masterclasses. We research, create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical sectors.

We believe in bringing you the best events incorporating:

  • In-depth analysis of the subject matter
  • Tools, techniques and information to immediately benefit your business
  • High level contact with expert speakers
  • Insight into new areas, refreshing your knowledge
  • Opportunities to learn from key opinion leaders, and to engage through Q&A
  • Sessions with leading professionals and to network before, during and after event

Our management team has more than 70 years collective experience in the conference industry and our long-term success has been established by providing a reliable and expert service. This gives you the delegate, the confidence and reassurance, in knowing that we have brought you the best speakers and content for 20 years. The SMi management team plays a very active role in the day to day running of the business and events and we look forward to meeting you at an event soon!

Most Popular Now

Aspirin green light for brain bleed stroke patient…

People who suffer a stroke caused by bleeding in the brain - known as brain haemorrhage - can take common medicines without raising their risk of another stroke, a major ...

Cancer cells are quick-change artists adapting to …

Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed...

APRINOIA Therapeutics awarded grant from The Micha…

APRINOIA Therapeutics, a clinical-stage biotechnology company with a pipeline of therapeutics and imaging diagnostics for neurodegenerative diseases, announces today that...

Benralizumab not effective reducing exacerbations …

More than 15.3 million people in the U.S. suffer from chronic obstructive pulmonary disease (COPD), which is the third leading cause of death in this country, according t...

Pfizer announces top-line results from Phase 3 Tri…

Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age wi...

Novartis phase II data for new inhaled combination…

Novartis announced today that new phase II data for IND/GLY/MF (QVM149), an investigational, once-daily, fixed dose combination asthma treatment containing indacaterol ac...

Cannabis use among older adults rising rapidly

Cannabis use among older adults is growing faster than any other age group but many report barriers to getting medical marijuana, a lack of communication with their docto...

New data show Symbicort reduces attacks in mild as…

New data from Novel START, an open-label trial designed to reflect real-world practice, has demonstrated the effectiveness of Symbicort Turbuhaler (budesonide/formoterol)...

Merck pioneers new effort to see MS from the insid…

Merck, a leading science and technology company, joins the global multiple sclerosis (MS) community in recognition of World MS Day, an initiative created by the Multiple ...

Amgen joins with community oncology networks for n…

Amgen (NASDAQ: AMGN), along with leading community oncology networks, today announced the launch of Amgen Community Oncology Research Collaborators (ACORC), a new initiat...

Bayer receives U.S. FDA breakthrough therapy desig…

Bayer announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for copanlisib (Aliqopa™) for the treatment of adult patie...

Novartis Kisqali significantly extends life in wom…

Novartis announced statistically significant overall survival (OS) results for Kisqali in combination with endocrine therapy[1]. The Phase 3 MONALEESA-7 trial evaluated K...